NetScientific PLC Vortex Announces Liquid Biopsy Study in NPJ
01 November 2017 - 10:00PM
RNS Non-Regulatory
TIDMNSCI
NetScientific PLC
01 November 2017
NetScientific plc
("NetScientific" or the "Company" or the "Group")
Vortex Biosciences Announces Publication of Liquid Biopsy Study
in Nature Partner Journals Genomic Medicine
London, UK - 1 November 2017 - NetScientific plc
("NetScientific", AIM:NSCI), the transatlantic healthcare IP
commercialisation group, announces an update from its portfolio
company, Vortex BioSciences, which today announced the publication
of "Workflow optimization of whole genome amplification and
targeted panel sequencing for CTC mutation detection" in Nature
Partner Journals (npj) Genomic Medicine on 1 November 2017. Source:
https://tinyurl.com/ybhuzpu4 DOI Number:
10.1038/s41525-017-0034-3
The peer-reviewed publication describes the use of Vortex's
technology to capture and examine circulating tumor cells (CTCs)
from patients with colorectal cancer. Vortex's technology allows
for an optimised workflow for performing whole genome amplification
(WGA) and targeted next-generation sequencing (NGS) on these
captured CTCs. The study was completed in collaboration with
Professor Stefanie Jeffrey, Chief of Surgical Oncology Research at
Stanford University School of Medicine.
Commenting on the news, Francois Martelet, Chairman of Vortex
BioSciences Inc. and CEO of NetScientific said: "We are pleased to
see the publication of high-impact research in the field of liquid
biopsy involving Vortex's VTX-1 platform, which we believe can give
researchers the opportunity to open new windows into understanding
cancer. This research marks an important step point in the
commercialisation journey for Vortex, with the paper demonstrating
the ability for CTCs collected by the VTX-1 machine to understand
cancer progression, enabling disease identification and
monitoring."
# # #
For more information, please contact:
NetScientific Tel: +44 (0)20 3514 1800
François R. Martelet,
M.D., CEO
Ian Postlethwaite,
CFO
Consilium Strategic
Communications Tel: +44 (0)20 3709 5700
Mary-Jane Elliott / netscientific@consilium-comms.com
Jessica Hodgson /
Chris Welsh / Laura
Thornton
Stifel Nicolaus Europe
Limited (NOMAD and Broker) Tel: +44 (0) 20 7710 7600
Jonathan Senior / David
Arch / Ben Maddison
Vortex Biosciences Tel: +1 (0) 415 823 7649
Steve Crouse steve@vortexbiosciences.com
About NetScientific
NetScientific is a transatlantic healthcare technology group
with an investment strategy focused on sourcing, funding and
commercialising technologies that significantly improve the health
and well-being of people with chronic diseases. For more
information, please visit the website at www.netscientific.net
Vortex Biosciences Announces Publication in NPJ Genomic Medicine
Describing Next Gen Sequencing of Pooled CTCs Isolated from
Colorectal Cancer Patients
The High Purity of CTCs Collected Using the VTX-1 Liquid Biopsy
System Enables Next Gen Sequencing Analysis
MENLO PARK, CA, November 01 - Vortex Biosciences, provider of
circulating tumor cell (CTC) capture systems, today announced the
publication of "Workflow optimization of whole genome amplification
and targeted panel sequencing for CTC mutation detection" in NPJ
Genomic Medicine from Nature Research on November 01. The peer
reviewed publication describes the use of the Vortex technology to
capture CTCs from colorectal cancer patients and apply an optimized
workflow for performing whole genome amplification (WGA) and
targeted next-generation sequencing (NGS) on these captured CTCs.
The research described in the paper was completed in collaboration
with Professor Stefanie Jeffrey, Chief of Surgical Oncology
Research at Stanford University School of Medicine. Performing NGS
on isolated CTC populations opens new windows into the real-time
understanding of a patient's evolving cancer.
Genomic mutation profiling of CTCs provides valuable information
for determining potential treatment paths in cancer. Here, targeted
NGS allows for the rapid detection of a variety of mutations from
CTCs in a single sample, expanding the opportunity for CTCs to be
used as a replacement for conventional tissue biopsies in the
identification of appropriate drug treatment and the monitoring of
cancer progression.
In this study, each step in the NGS workflow was tested,
including optimization of DNA extraction, evaluation of different
WGA methods with characterization by targeted MiSeq NGS. Optimal
methods for genomic analysis of FFPE tissue samples and rare pooled
CTCs were determined. The overall workflow was further tested on
samples from patients with metastatic colorectal cancer, assaying
both liver tissue metastases and CTCs. CTCs were isolated utilizing
Vortex technology, which captured both single-cell and clustered
CTCs. This publication confirms the successful use of the Vortex
technology in targeted NGS analysis of pooled CTCs.
"We're excited that the purity of the CTC sample collected by
the VTX-1 Liquid Biopsy System enables Next Gen Sequencing," said
Elodie Sollier-Christen, Chief Scientific Officer of Vortex
Biosciences. "Understanding the oncogenic mutations that are the
drivers of a patient's disease is now simpler to identify and
monitor throughout treatment."
The Vortex VTX-1 Liquid Biopsy System utilizes a proprietary
microfluidic chip to capture CTCs in micro-scale vortices based on
their size and deformability. While the CTCs are trapped in these
micro-scale vortices, the red and white blood cells flow past,
allowing for recovery of a highly enriched CTC sample. This unique
approach to CTC isolation results in the capture of viable CTCs
that are high in purity making a sensitive and accurate analysis by
targeted NGS achievable. Furthermore, CTCs are captured and
collected unbiased by their molecular characteristics.
Interestingly, most of the CTCs isolated from the colorectal
patients in this study did not show any cytokeratin (CK) or
epithelial cell adhesion molecule (EpCAM) expression, but displayed
mainly mesenchymal features (vimentin and N-Cadherin). CTCs
negative for epithelial markers (CK, EpCAM), would have been missed
by many CTC isolation approaches that utilize these epithelial
markers for CTC capture and detection.
The fully automated VTX-1 Liquid Biopsy System from Vortex
represents the next step in CTC isolation. With a cancer cell
recovery of 65-75%, best-in-class CTC purity, and collection of
label-free viable CTCs ready for downstream analysis, the VTX-1
offers the best CTC samples available today.
About Vortex Biosciences
Vortex Biosciences is a cancer research and diagnostics company
that integrates cancer biology, microfluidic engineering and
informatics to develop tools for isolating and characterizing
circulating tumor cells. The Vortex VTX-1 instrument harvests
intact circulating tumor cells from whole blood samples for use in
downstream research and clinical applications such as patient
stratification in clinical trials, monitoring disease progression
and drug treatment effectiveness. With a mission to enable
noninvasive diagnosis of cancer and real-time monitoring throughout
a patient's treatment, Vortex is at the forefront of accelerating
cancer research and improving patient outcomes. Vortex is a core
subsidiary of NetScientific plc, a transatlantic healthcare
technology group with an investment strategy focused on sourcing,
funding and commercializing technologies that significantly improve
the health and well-being of people with chronic diseases. For more
information, visit www.vortexbiosciences.com.
# # #
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRABBBMTMBIMBJR
(END) Dow Jones Newswires
November 01, 2017 07:00 ET (11:00 GMT)
Netscientific (LSE:NSCI)
Historical Stock Chart
From Apr 2024 to May 2024
Netscientific (LSE:NSCI)
Historical Stock Chart
From May 2023 to May 2024